Tolerability and adherence to adjuvant abemaciclib in hormone receptor-positive, HER2-negative, node-positive high-risk early breast cancer: a real-world study
DOI:
https://doi.org/10.2340/1651-226X.2026.45961Keywords:
Abemaciclib, Real-world data, Healthcare utilisation, Tolerability, Breast cancer, HR-positive, Dose titrationAbstract
Background and purpose: Abemaciclib in addition to adjuvant endocrine therapy for hormone receptor positive (HR+) breast cancer improves disease free survival (IDFS) and overall survival (OS). However, treatment-related adverse events may lead to early discontinuation. Sahlgrenska University Hospital implemented a gradual increase in initial dosing, with the intention to improve tolerability and adherence.
Patient/material and methods: This retrospective observational study described adherence, tolerability and healthcare utilization associated with a gradual dose increase of adjuvant abemaciclib. A total of 69 patients aged 31–81 years were treated at Sahlgrenska University Hospital between 1st of April 2023 and 1st of April 2025 with cut-off September 5th, 2025. Clinical encounters and treatment outcomes were extracted from medical records and analyzed using descriptive statistics.
Results: Patients were older and had worse Eastern Cooperative Oncology Group status compared with the monarchE registrational trial. At 12 and 26 weeks, 34 patients (49%) and 25 patients (36%) remained on the full dose of abemaciclib, respectively. Overall, 65 patients (94.2%) and 58 patients (84%) remained on treatment at any dose at 12 and 26 weeks. Treatment discontinuation was mainly driven by low grade adverse events (grade 1–2). During the study period 1069 clinical encounters were recorded; 15 patients (22%) had at least one emergency care encounter and seven (10%) required hospital admission.
Interpretation: The gradual dose increase strategy resulted in fewer patients maintaining the full dose at 12 weeks compared with monarchE and TRADE trials, while overall treatment persistence remained high. Treatment discontinuation was primarily driven by cumulative low-grade toxicity and healthcare utilization was considerable.
Downloads
References
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–98 DOI: https://doi.org/10.1200/JCO.20.02514
Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77–90 DOI: https://doi.org/10.1016/S1470-2045(22)00694-5
Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–37 DOI: https://doi.org/10.1007/s10637-014-0120-7
Johnston S, Martin M, O’Shaughnessy J, Hegg R, Tolaney SM, Guarneri V, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155–165. DOI: https://doi.org/10.1016/j.annonc.2025.10.005
Rastogi P, O’Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, et al. Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol. 2024;42(9):987–93 DOI: https://doi.org/10.1200/JCO.23.01994
Rugo HS, O’Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616–27 DOI: https://doi.org/10.1016/j.annonc.2022.03.006
Mayer EL, Trapani D, Kim SE, Faggen M, Sinclair N, Sanz-Altamira P, et al. TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer. Ann Oncol. 2026;37(1):117–124 DOI: https://doi.org/10.1016/j.annonc.2025.09.141
Commission E. Verzenios 50 mg, 100 mg, 150 mg film-coated tablets: summary of product characteristics. Summary of product characteristics. Brussels: European Commission; 2020.
Goetz MP, Cicin I, Testa L, Tolaney SM, Huober J, Guarneri V, et al. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer. 2024;10(1):34 DOI: https://doi.org/10.1038/s41523-024-00639-1
Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080–91 DOI: https://doi.org/10.1056/NEJMoa2305488
Jacobsen IC, Berg T, Jensen MB, Knop AS. Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study. Acta Oncol. 2025;64:1531–9 DOI: https://doi.org/10.2340/1651-226X.2025.44003
Karihtala P. How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy? Acta Oncol. 2025;64:815–29 DOI: https://doi.org/10.2340/1651-226X.2025.43645
Jongbloed EM, Blommestein HM, van Schoubroeck HM, Martens JWM, Wilting SM, Uyl-de Groot CA, et al. Cost-effectiveness of abemaciclib in early breast cancer patients: one size fits all or tailoring to patients’ needs? Breast Cancer (Dove Med Press). 2023;15:147–61 DOI: https://doi.org/10.2147/BCTT.S387375
Behan E, Veenstra DL, Bansal A. Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with a CDK4/6i in the first-line setting. J Manag Care Spec Pharm. 2025;31(1):6–14 DOI: https://doi.org/10.18553/jmcp.2025.31.1.6
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Carl Rosander, Karolina Larsson , Per Karlsson
This work is licensed under a Creative Commons Attribution 4.0 International License.
